Dieter Horsch
Elite in Carcinoid Syndrome

Dieter Horsch

Robert Koch Allee 9, 
Bad Berka, TH, DE 
Elite in Carcinoid Syndrome
Robert Koch Allee 9, 
Bad Berka, TH, DE 
OverviewLocationsClinical Research

Overview

Dieter Horsch practices in Bad Berka, Germany. Mr. Horsch is rated as an Elite expert by MediFind in the treatment of Carcinoid Syndrome. His top areas of expertise are Neuroendocrine Tumor, Carcinoid Syndrome, Pancreatic Islet Cell Tumor, and Diarrhea.

His clinical research consists of co-authoring 53 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 11 articles in the study of Carcinoid Syndrome.

Gender
Male

Locations

Robert Koch Allee 9, Bad Berka, TH 99437, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Randomized Open Label Study to Compare the Efficacy and Safety of Everolimus Followed by Chemotherapy With Streptozotocin- Fluorouracilo (STZ-5FU) Upon Progression or the Reverse Sequence, in Advanced Progressive Pancreatic NETs (pNETs)
Randomized Open Label Study to Compare the Efficacy and Safety of Everolimus Followed by Chemotherapy With Streptozotocin- Fluorouracilo (STZ-5FU) Upon Progression or the Reverse Sequence, in Advanced Progressive Pancreatic NETs (pNETs)
Enrollment Status: Completed
Publish Date: May 11, 2025
Intervention Type: Drug
Study Drug: STZ-5FU
Study Phase: Phase 3
A Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide Autogel®/Depot 120 mg Plus BSC vs. Placebo Plus BSC for Tumour Control in Subjects With Well Differentiated, Metastatic and/or Unresectable, Typical or Atypical, Lung Neuroendocrine Tumours
A Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide Autogel®/Depot 120 mg Plus BSC vs. Placebo Plus BSC for Tumour Control in Subjects With Well Differentiated, Metastatic and/or Unresectable, Typical or Atypical, Lung Neuroendocrine Tumours
Enrollment Status: Terminated
Publish Date: July 06, 2022
Intervention Type: Drug
Study Phase: Phase 3
Best Therapy for Patients With Neuroendocrine Tumors
Best Therapy for Patients With Neuroendocrine Tumors
Enrollment Status: Completed
Publish Date: March 21, 2017
View 2 Less Clinical Trials

53 Total Publications

Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study.
Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study.
Journal: Endocrine-related cancer
Published: December 11, 2023

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Horsch's expertise for a condition
ConditionClose
    View All 7 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile